BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...Robin Sawka, Biocentury Staff Former Kindred Healthcare CEO Paul Diaz has become president and CEO of Myriad Genetics...
...NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus Pharmaceuticals Inc. Bicycle Therapeutics plc MiMedx Group Inc. Oasmia Pharmaceutical AB Myriad Genetics...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after...
BioCentury | Dec 30, 2019
Company News

FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

...patients who have not progressed on platinum chemotherapy. The agency also approved BRACAnalysis CDx from Myriad Genetics...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...products in Russia and six other countries to Stada Arzneimittel AG (Xetra:SAZ). Myriad cuts guidance Myriad Genetics...
...Associate Editor BCX7353 Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad Genetics...
BioCentury | Nov 5, 2019
Company News

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

...to relieve neuroinflammation weren’t effective. For example, EnVivo Pharmaceuticals Inc., now Forum Pharmaceutical Inc., and Myriad Genetics...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Kintai is developing tissue-targeted oral small molecules that mimic microbes’ therapeutic effects. Molecular diagnostics company Myriad Genetics...
...first physician CMO of Myriad Neuroscience, which was formerly known as Assurex Health Inc. before Myriad Genetics...
...acquired the unit in 2016. Assurex’s CMO and CSO was Bryan Dechairo, who is now Myriad Genetics’...
BioCentury | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

...to catch fast-growing BRCA1 mutant ovarian cancers earlier. Whereas conventional diagnostics, such as that from Myriad Genetics...
...Menlo Park, Calif. Guardant Health Inc. (NASDAQ:GH), Redwood City, Calif. Microsoft Corp. (NASDAQ:MSFT), Redmond, Wash. Myriad Genetics...
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...Myriad falls on sales forecast, GeneSight concerns Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday...
...funding round from an investor consortium led by Esco. BioCentury Staff pretomanid, nitroimidazopyran (PA-824) AbbVie Inc. Akari Therapeutics plc Allergan plc Myriad Genetics...
BioCentury | Aug 9, 2019
Finance

Earnings on deck

...hours on U.S. exchanges Company Date Pre/post mkt 2Q19 EPS est 2Q18 EPS Expected chg Myriad Genetics...
BioCentury | Aug 1, 2019
Company News

With GeneSight health economics data in hand, Myriad wins UnitedHealth coverage

...or anxiety and who have failed at least one prior medication to treat their condition. Myriad Genetics...
...medications. Rogers said other undisclosed payers also cover GeneSight. Elizabeth S. Eaton, Staff Writer GeneSight Psychotropic Assurex Health Inc. Myriad Genetics...
Items per page:
1 - 10 of 834